Click here to download PDF Version of the final programme (1.8 MB)

Search through the abstracts in detail! Click here to start!

About the Agenda Builder

The agenda builder is a simple, light-weight tool to manage your schedule. There are filters to narrow your search by day, track and/or presenter.

  • To use, simply click the "Add to my agenda" link. The  selected item will remain in memory indefinitely. 
  • Limitation: It will only "remember" the computer employed AND as long as you do not erase your "cookies".

:   :   :

:   :   Search

HPV 2010
 
Programme

>> Day 4 - Tuesday, July 6, 2010

Time Description Room Expand all sessions
07:00 AM
Early-Morning Workshop - Young Researchers Community of Practice
 516bcd
 Show details
07:00 AM
    L   
How to succeed in an academic career
François Coutlée [Bio]
Professor, Microbiology and Immunology, Université de Montréal
Montreal, Canada
516bcd
 Add to my agenda
07:00 AM
    L   
How to succeed in an academic career
Eduardo Franco [Bio]
Professor and Director, Division of Cancer Epidemiology, McGill University
Montreal, Canada
516bcd
 Add to my agenda
07:00 AM
Early-Morning Workshop - Emerging Nations Capacity Building – WHO/PAHO: Cervical Cancer Prevention
 515ab
 Add to my agenda
07:15 AM
Morning Symposium - Sponsored by Hologic – Cervista® HPV HR CLINICAL DATA: EMERGING PERSPECTIVES
Chair(s):
Michael A. Gold, Nashville, USA
 710b
 Show details

   L   
Understanding HR HPV prevalence across studies in the United States
Jennifer S. Smith
Department of Epidemiology, University of North Carolina
Raleigh , USA
710b
 Add to my agenda

   L   
Cervista HPV clinical trial and laboratory experience
Marilyn C. Olson
,
710b
 Add to my agenda

   L   
Application of the Cervista HPV HR test across different US study populations
710b
 Add to my agenda
08:30 AM
Plenary - HPV Screening
Chair(s):
Joakim Dillner, Malmö, Sweden
Jacques Archambault
 517cd
 Show details
08:30 AM
    L   
New Molecular Markers for Cervical Cancer Screening: Distinguishing Hype from Hope
Phillip Castle [Bio]
Investigator, National Cancer Institute, National Institutes of Health
Bethesda, USA
517cd
 Add to my agenda
09:00 AM
    L   
Are We Ready to Move to HPV Testing for Primary Screening?
Jack Cuzick [Bio] [Abstract]
John Snow Professor of Epidemiology, Head of Department, Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, Queen Mary, University of London, Wolfson Institute of Preventive Medicine
London, United Kingdom
517cd
 Add to my agenda
09:30 AM
    L   
Cervical Cancer Screening in Developing Countries
Rengaswamy Sankaranarayanan [Bio] [Abstract]
Head, Early Detection & Prevention Group (EDP) and Screening Group (SCR), International Agency for Research on Cancer
Lyon,
517cd
 Add to my agenda
10:30 AM
Satellite Symposium - Cochrane Workshop: Use of molecular markers potentially usable for cervical cancer screening or triage of screen-positive women: the template of p16.
More Details...
Chair(s):
Christine Bergeron, Cergy Pontoise, France
 516abc
 Show details
10:30 AM
    L   
Introduction
Marc Arbyn
Unit of Cancer Epidemiology, Scientific Institute of Public Health
Brussels, Belgium
516abc
 Add to my agenda
10:40 AM
    L   
The molecular pathways from HPV infection to development of cervical cancer, rational use of biomarkers
Magnus von Knebel Doeberitz
Director and Professor, Department of Applied Tumor Biology, University of Heidelberg Im Neuenheimer
Heidelberg, Germany
516abc
 Add to my agenda
10:55 AM
    L   
How to evaluate molecular markers usable for cervical cancer screening?
Marc Arbyn
Unit of Cancer Epidemiology, Scientific Institute of Public Health
Brussels, Belgium
516abc
 Add to my agenda
11:05 AM
    L   
p16 immunostaining of cervical cell samples and biopsies, preparation, interpretation, new results from well-designed studies
Christine Bergeron
Cergy Pontoise, France
516abc
 Add to my agenda
11:25 AM
    L   
p16 triage of HPV-positive women
Francesca Maria Carozzi
Florence, Italy
516abc
 Add to my agenda
11:25 AM
    L   
p16 triage of HPV-positive women
Guglielmo Ronco
Responsible Unit for cervical screening evaluation, Unit of Cancer Epidemiology, C.E.R.M.S., University of Turin
Torino, Italy
516abc
 Add to my agenda
11:35 AM
    L   
Evaluation of p16 immunostaining- approaches towards standardization
Nicolas Wentzensen
Investigator, Hormonal and Reproductive Epidemiology Branch, National Cancer Institute, Division of Cancer epidemiology & Genetics
, USA
516abc
 Add to my agenda
11:35 AM
    L   
Evaluation of p16 immunostaining- approaches towards standardization
D. Solomon
,
516abc
 Add to my agenda
11:50 AM
    L   
Discussion and conclusion
Christine Bergeron
Cergy Pontoise, France
516abc
 Add to my agenda
11:50 AM
    L   
Discussion and conclusion
Nicolas Wentzensen
Investigator, Hormonal and Reproductive Epidemiology Branch, National Cancer Institute, Division of Cancer epidemiology & Genetics
, USA
516abc
 Add to my agenda
10:30 AM
Oral Communications - Basic Science 4
Chair(s):
Paul F. Lambert, Madison, USA
 517b
 Show details
10:30 AM
    L   
Papillomaviruses Activate the ATM Damage Pathway Upon Differentiation for Genome Amplification
Laimonis A. Laimins [Abstract]
Guy and Anne Youmans Professor and Chair of Microbiology-Immunology, Northwestern University, Feinberg School of Medicine
Chicago, USA
517b
 Add to my agenda
10:45 AM
    L   
Benzo[a]pyrene Increases HPV31b Titer through Erk1/2 Signaling.
Craig Meyers [Abstract]
Professor of Microbiology and Immunology, The Huck Institutes Of The Life Sciences
Hershey, USA
517b
 Add to my agenda
11:00 AM
    L   
Human Papillomavirus DNA Amplification and Persistence Require MAP Kinases
Tom Broker [Bio] [Abstract]
Department of Biochemistry & Molecular Genetics, University of alabama at Birmingham
Birmingham, USA
517b
 Add to my agenda
11:15 AM
    L   
Alternative Splicing of HPV16 E6/E6* early mRNA is coupled to EGF-signaling via Erk activation
Simone Rosenberger [Abstract]
Heidelberg, Germany
517b
 Add to my agenda
11:30 AM
    L   
Human Keratinocytes are Immortalized by a Rho Kinase Inhibitor
Sandra Chapman [Abstract]
Fairfax, USA
517b
 Add to my agenda
11:45 AM
    L   
Role of Cyclin-dependent Kinase 1 in HPV E7-induced Endoreduplication
Jason Chen [Abstract]
Worcester, USA
517b
 Add to my agenda
10:30 AM
Oral Communications - Clinical Science 4
Chair(s):
Kari Syrjanen, Turku, Finland
Herbert J. Pfister, Koeln, Germany
 517a
 Show details
10:30 AM
    L   
Hpv Infection Clearance Among Men Ages 18-70 Years: The Him Study
Anna R. Giuliano [Bio] [Abstract]
Chair, Department of Cancer Epidemiology and Genetics; Program Leader, Risk Assessment, Detection, and Intervention Program; H. Lee Moffitt Cancer Center and Research Institute
Tampa, USA
517a
 Add to my agenda
10:45 AM
    L   
Serum antibody response following alpha 9 HPV infection in young men
Zoe Edelstein [Abstract]
Seattle, USA
517a
 Add to my agenda
11:00 AM
    L   
Circumcision and acquisition of high-risk HPV infection in young men
Kelley M. VanBuskirk [Abstract]
Seattle, US
517a
 Add to my agenda
11:15 AM
    L   
The effect of male circumcision on incident and persistent penile HPV infections in men from Kenya
Jennifer S. Smith [Abstract]
Department of Epidemiology, University of North Carolina
Raleigh , USA
517a
 Add to my agenda
11:30 AM
    L   
Association Between HPV-16 L1 VLP Serum Antibodies and Future Risk of Genital HPV Infections in Men
Beibei Lu [Abstract]
TAMPA, USA
517a
 Add to my agenda
11:45 AM
    L   
HPV transmission in heterosexually active couples over 12 months
Zizipho Mbulawa [Abstract]
Cape Town, South Africa
517a
 Add to my agenda
10:30 AM
Oral Communications - Epidemiology & Public Health 4
Chair(s):
Philip Davies, Brussels, Belgium
Sam Ratnam, St. John's, Canada
 524
 Show details
10:30 AM
    L   
Monitoring HPV types in the general female population in the Nordic countries
Joakim Dillner [Bio] [Abstract]
Professor in infectious disease epidemiology at Karolinska Institutet, Stockholm, Sweden
Malmö, Sweden
524
 Add to my agenda
11:00 AM
    L   
EXPLORING THE CONSEQUENCES OF CROSS-PROTECTION AND POLYVALENT VACCINES FOR SCREENING PRACTICE IN THE NETHERLANDS
Veerle Coupé [Abstract]
Amsterdam, Netherlands
524
 Add to my agenda
11:15 AM
    L   
I just signed": Factors influencing decision-making for school-based HPV vaccination in Australia"
Spring Chenoa Cooper Robbins [Abstract]
Westmead, Australia
524
 Add to my agenda
11:30 AM
    L   
HPV seroprevalence and type distribution in Europe: results from the EPIC cohort
E. Roura [Abstract]
L'Hospitalet de Llobregat, Spain
524
 Add to my agenda
11:45 AM
    L   
Factors associated with human papillomavirus (HPV) vaccine introduction in developing countries: the similarities across diverse countries
Proma Paul [Abstract]
Seattle, USA
524
 Add to my agenda
10:30 AM
Satellite Symposium - Women Against Cervical Cancer (WACC): Community mobilization: What We can ALL do About Cervical Cancer
 525ab
 Show details
10:30 AM
    L   
-
Brigitte Leclerc
,
525ab
 Add to my agenda
10:35 AM
    L   
Introduction. What women need and what women can do to fight HPV and cervical cancer? Presentation of WACC Voice of Women Study 1.
Teresa Norris
Brossard, Canada
525ab
 Add to my agenda
10:45 AM
    L   
What can women and doctors do against cervical cancer?
Miriam Cremer
New York, USA
525ab
 Add to my agenda
10:55 AM
    L   
What can science do for community mobilization?
Patti Gravitt [Bio]
Assistant Professor, Epidemiology; Molecular Microbiology and Immunology, John Hopkins Bloomberg School Of Public Health(JHSPH)
Baltimore, USA
525ab
 Add to my agenda
11:05 AM
    L   
How to work with women in the community?
Shobha Krishnan
New York, U.S.A
525ab
 Add to my agenda
11:15 AM
    L   
What can women in politics & institutions do to fight cervical cancer?
525ab
 Add to my agenda
11:25 AM
    L   
What can we learn from civil society? What HPV (education, advocacy & prevention) can learn from HIV (education, advocacy & prevention)? And vice versa.
Vanina Laurent
Founding president of Univers-Elles women leaders club (Lyon, France) and Merck vaccine policy director
,
525ab
 Add to my agenda
11:35 AM
    L   
The necessary mobilization of all actors. Role of associations and advocacy groups to help fight cervical cancer, with doctors and all stakeholders - Presentation of WACC International Foundation, networks and projects.
Joseph Monsonego
Medical Director, Institute of the Cervix; President of EUROGIN and WACC International Foundation
Paris, France
525ab
 Add to my agenda
11:50 AM
    L   
Conclusion
Teresa Norris
Brossard, Canada
525ab
 Add to my agenda
12:30 PM
Satellite Lunch Symposium - Sponsored by Merck & Dohme - OUTSTANDING SCIENTIFIC & PUBLIC HEALTH ISSUES IN THE HPV FIELD
 710
 Show details

   L   
Welcome and Introduction
Marc Steben [Bio]
HPV 2010 Conference Chair; Médecin conseil, Direction des risques biologiques et de la santé au travail, Institut national de santé publique du Québec
Montreal, Canada
710
 Add to my agenda

   L   
Gender neutral vaccination – The path forward
Anna R. Giuliano [Bio]
Chair, Department of Cancer Epidemiology and Genetics; Program Leader, Risk Assessment, Detection, and Intervention Program; H. Lee Moffitt Cancer Center and Research Institute
Tampa, USA
710
 Add to my agenda

   L   
HPV vaccination of sexually active women: What matters to the clinician
Elmar Joura
Vienna, Austria
710
 Add to my agenda

   L   
The real life impact of GARDASILTM: An update of the Australian experience
Andrew Grulich
Sydney, Australia
710
 Add to my agenda

   L   
Evaluating the impact of female HPV vaccination in low-coverage settings: The influence of male partners
Ann Burchell [Bio]
Division of Cancer Epidemiology, Departments of Oncology and Epidemiology and Biostatistics, McGill University
Montreal,
710
 Add to my agenda

   L   
Panel discussion and closing remarks
Eduardo Franco [Bio]
Professor and Director, Division of Cancer Epidemiology, McGill University
Montreal, Canada
710
 Add to my agenda
02:00 PM
Oral Communications - Clinical Science 5
Chair(s):
Joseph Monsonego, Paris, France
Christine Clavel, Reims, France
 517a
 Show details
02:00 PM
    L   
p16/Ki-67 Dual-stained cytology in screening for cervical disease - Results from the PALMS Trial in over 27,000 women
Christine Bergeron [Abstract]
Cergy Pontoise, France
517a
 Add to my agenda
02:15 PM
    L   
Prognostic value of p16INK4A immunostaining and of genotyping for the risk of new high-grade lesions among HPV positive women.
Guglielmo Ronco [Abstract]
Responsible Unit for cervical screening evaluation, Unit of Cancer Epidemiology, C.E.R.M.S., University of Turin
Torino, Italy
517a
 Add to my agenda
02:30 PM
    L   
Performance of careHPV(TM) testing, VIA, and cytology in the START-UP* demonstration project in Nicaragua
Jose A. Jeronimo [Bio] [Abstract]
Director START-UP Project, Reproductive Health, PATH
Seattle, USA
517a
 Add to my agenda
02:45 PM
    L   
Triage Of Women With A Positive Baseline Test For Human Papillomavirus DNA
Dirk van Niekerk [Abstract]
Clinical Assistant Professor, Department of Pathology & Laboratory Medicine, University of British Columbia; Medical Leader, Cervical Cancer Screening Program; Director, Cervical Cancer Screening Laboratory
Vancouver, Canada
517a
 Add to my agenda
03:00 PM
    L   
Cell By Cell Quantification of HPV E6/E7 mRNA expression Increases the Positive Predictive Value of Cervical Cancer Screening
Bruce K. Patterson [Abstract]
Campbell, USA
517a
 Add to my agenda
03:15 PM
    L   
Use of HPV mRNA test in HPV triaging
Sveinung Sorbye [Abstract]
Tromso, Norway
517a
 Add to my agenda
02:00 PM
Satellite Symposium - Cochrane Workshop: Reviews on prevention of HPV-related disease - part 1
More Details...
Chair(s):
Achim Schneider, Berlin, Germany
E. Paraskevaidis
 516abc
 Show details

   L   
Welcome
Marc Steben [Bio]
HPV 2010 Conference Chair; Médecin conseil, Direction des risques biologiques et de la santé au travail, Institut national de santé publique du Québec
Montreal, Canada
516abc
 Add to my agenda

   L   
Introduction
Marc Arbyn
Unit of Cancer Epidemiology, Scientific Institute of Public Health
Brussels, Belgium
516abc
 Add to my agenda

   L   
Overview of recent systematic reviews
Maria Kyrgiou
London, UK
516abc
 Add to my agenda
02:30 PM
    L   
One of the primary screening trials contributing to an individual-patient data meta-analysis comparing testing with cytology, HPV or the combination of cytology & HPV
Marie-Hélène Mayrand [Bio]
Chercheur, Faculté de médecine, Départements de Gynécologie et de Médecine Sociale et Préventive, Université de Montréal et CHUM
Montréal, Canada
516abc
 Add to my agenda

   L   
Pooling of data of the RCTS comparing HPV and cytology-based screening
Marc Arbyn
Unit of Cancer Epidemiology, Scientific Institute of Public Health
Brussels, Belgium
516abc
 Add to my agenda

   L   
Pooling of data from case-control or cohort studies addressing effectiveness of cytological cervical cancer screening: P Sasieni
P. Sasieni
,
516abc
 Add to my agenda

   L   
Additional data needed for a systematic review on efficacy of prophylactic HPV vaccination
Allan Hildesheim [Bio]
Chief, Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health
Rockville, USA
516abc
 Add to my agenda

   L   
Farewell and see you in Berlin
Achim Schneider
Professor and Chairman, Charite Campus Benjamin Franklin, Gynecology, CCBF Universitätsmedizin
Berlin, Germany
516abc
 Add to my agenda
02:00 PM
Oral Communications - Basic Science 5
Chair(s):
Daniel DiMaio, New Haven, USA
Karl Munger, Boston, USA
 517b
 Show details
02:00 PM
    L   
Tumour prevention in HPV8 transgenic mice by HPV8-E6 DNA vaccination.
Gian Paolo Marcuzzi [Abstract]
Cologne, Germany
517b
 Add to my agenda
02:15 PM
    L   
Heterologous compared to homologous prime-boost immunization results in higher CTL frequencies but not in higher anti-tumor responses
Mateusz Walczak [Abstract]
Groningen, The Netherlands
517b
 Add to my agenda
02:30 PM
    L   
Direct Longitudinal comparison over 12 month of T cell responses to prophylactic HPV vaccines.
Andreas M. Kaufmann [Abstract]
Berlin, Germany
517b
 Add to my agenda
02:45 PM
    L   
KIR3DS1, KIR2DS1, KIR2DS5 protect against development of severe recurrent respiratory papillomatosis (RRP).
Vincent R. Bonagura [Abstract]
Great Neck, USA
517b
 Add to my agenda
03:00 PM
    L   
Innovative DNA Vaccine for Human Papilloma Virus (HPV)-associated Head and Neck Cancer
Annie Wu [Abstract]
Stevenson, USA
517b
 Add to my agenda
03:15 PM
    L   
Novel Immunotherapy to regress genital HPV-tumors in an orthotopic murine model
Loane Decrausaz [Abstract]
Lausanne, Switzerland
517b
 Add to my agenda
02:00 PM
Canadian Initiatives in Global HPV Prevention and Care - Society of Gynecologic Oncology Canada, Society of Canadian Colposcopy and Centre for Infectious Diseases (ICID)
More Details...
 515ab
 Add to my agenda
02:00 PM
Oral Communications - Epidemiology & Public Health 5
Chair(s):
Silvia Franceschi, Lyon, France
Howard Strickler, Bronx, USA
 524
 Show details
02:00 PM
    L   
The role of genetic variation in HPV16 in the development of cervical cancer worldwide
Gary M. Clifford [Abstract]
Scientist, Infections and Cancer Epidemiology Group IARC
Lyon, France
524
 Add to my agenda
02:15 PM
    L   
Costs of cervical cancer screening and treatment using VIA with cryotherapy in Ghana: the importance of scale
Rosa Legood [Abstract]
London, Canada
524
 Add to my agenda
02:30 PM
    L   
Incidence rates of anogenital warts in Germany
Edeltraut Garbe [Abstract]
Bremen, Germany
524
 Add to my agenda
02:45 PM
    L   
Clearance of human papillomavirus following treatment for cervical dysplasia: a prospective study
Elya Moore [Abstract]
Parkville, Australia
524
 Add to my agenda
03:00 PM
    L   
Detection of Cervical Cancer Precursors and Associated HPV in the United States: HPV-IMPACT Preliminary Results
Susan Hariri [Abstract]
Atlanta, USA
524
 Add to my agenda
03:15 PM
    L   
Human Papillomavirus Vaccine: How effective is the uptake in Indigenous Australian Females?
Telphia-Leanne Joseph [Abstract]
Westmead, Australia
524
 Add to my agenda
04:00 PM
Oral Communications - Basic Science 6
Chair(s):
Michelle A. Ozbun, Albuquerque, USA
Zhi-Ming Zheng, Bethesda, USA
 517b
 Show details
04:00 PM
    L   
Profile of the HPV 16 and 18 variants in the quadrivalent vaccine phase 2 clinical trials
Janine Bryan [Abstract]
West Point, USA
517b
 Add to my agenda
04:15 PM
    L   
Differential Biological Activities of two Human Papillomavirus 16 E6 Protein Variants with Low and High Prevalence in Cervical Cancer
Ingeborg Zehbe [Abstract]
Career Scientist, Northern Ontario School of Medicine
Thunder Bay, Canada
517b
 Add to my agenda
04:30 PM
    L   
Analysis of HPV16 variant and host population evolution and dynamics
Zigui Chen [Abstract]
Bronx, USA
517b
 Add to my agenda
04:45 PM
    L   
Construction of a complete transcription map of HPV18 in productive viral infection
Xiaohong Wang [Abstract]
Bethesda, USA
517b
 Add to my agenda
05:00 PM
    L   
Sequence Variation and Lineage Classification System for HPV58 : A Worldwide Perspective
Jo L.K. Cheung [Abstract]
Hong Kong, Hong Kong SAR, China
517b
 Add to my agenda
05:15 PM
    L   
GENOMIC DIVERSITY OF HPV 11: A STUDY ON 63 ISOLATES
Polona J. Maver [Abstract]
Ljubljana, Slovenia
517b
 Add to my agenda
04:00 PM
Oral Communications - Clinical Science 6
Chair(s):
J. Thomas Cox, Santa Barbara, USA
Yang Ke, Beijing, China
 517a
 Show details
04:00 PM
    L   
Absolute risks of CIN and cancer in a 16-year prospective study of type-specific HPV infection
Mark Schiffman [Bio] [Abstract]
Senior Investigator, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health
Rockville, USA
517a
 Add to my agenda
04:15 PM
    L   
Risk for CIN 2 regression and progression in adolescents and young women
Anna-Barbara Moscicki [Bio] [Abstract]
Professor of Pediatrics and Director for Clinical Services, University of California
San Francisco, USA
517a
 Add to my agenda
04:30 PM
    L   
HPV 16 physical state and viral load as predictive biomarkers for persistence and high-grade cervical neoplasia_>_ CIN3?
Anna Manawapat [Abstract]
Tuebingen, Germany
517a
 Add to my agenda
04:45 PM
    L   
Longitudinal study of the role of new and persistent HPV infections for the long-term risk of CIN3 or cancer
Susanne Krüger Kjær [Abstract]
Epidemiologist, Division for Cancer Epidemiology, Danish Cancer Society Research Center
Copenhagen, Denmark
517a
 Add to my agenda
05:00 PM
    L   
Colposcopic 7-years follow-up of women with persist HRHPV infection.
Kristina Elfgren [Abstract]
Stockholm, Sweden
517a
 Add to my agenda
05:15 PM
    L   
Epidemiologic Study of anti HPV16/18 seropositivity and subsequent risk of HPV16 and 18 infections
Mahboobeh Safaeian [Abstract]
Rockville, USA
517a
 Add to my agenda
04:00 PM
Oral Communications - Epidemiology & Public Health 6
Chair(s):
Geoffrey Garnett, London, UK
Jorma Paavonen, Helsinki, Finland
 524
 Show details
04:00 PM
    L   
Seroprevalence of antibodies against HPV types 16 and 18 in four continents: The IARC HPV Prevalence Surveys
Silvia Franceschi [Bio] [Abstract]
Head, Infections and Cancer Epidemiology Group Head, Section of Infections, International Agency for Research on Cancer
Lyon, France
524
 Add to my agenda
04:15 PM
    L   
Imputation of HPV16 Complete Genome Sequences and Epidemiological Analysis
Benjamin Smith [Abstract]
New York, United States
524
 Add to my agenda
04:30 PM
    L   
Competition of vaccine and non-vaccine HPV types in Finnish population before the era of mass HPV vaccination
Marko Merikukka [Abstract]
Oulu, Finland
524
 Add to my agenda
04:45 PM
    L   
The QOLIGEN study: Investigation of quality of life loss, duration of episode and treatment costs associated with genital warts in the UK
Charles JN Lacey [Bio] [Abstract]
Professor of Medicine & Honorary Reader in Sexual Health and HIV Medicine, The Hull York Medical School
York, United Kingdom
524
 Add to my agenda
05:00 PM
    L   
Secular trends of HPVdistribution in invasive cervical cancer, Colombia 1950-2000
Gustavo Hernandez-Suarez [Abstract]
Bogota, DC, Colombia
524
 Add to my agenda
05:15 PM
    L   
The Politics of HPV Vaccination Policy Formation in the United States
Sara Abiola [Abstract]
Boston, USA
524
 Add to my agenda
04:00 PM
Satellite Symposium - Cochrane Workshop: Cochrane reviews on prevention of HPV-related disease - part 2
More Details...
Chair(s):
Pierre Martin-Hirsch, Preston, UK
 516abc
 Show details
04:00 PM
    L   
Introduction
Marc Arbyn
Unit of Cancer Epidemiology, Scientific Institute of Public Health
Brussels, Belgium
516abc
 Add to my agenda
04:10 PM
    L   
IVP meta-analysis (1): RCT comparing performance of cytology- with H¨PV based screening for cervical cancer
Guglielmo Ronco
Responsible Unit for cervical screening evaluation, Unit of Cancer Epidemiology, C.E.R.M.S., University of Turin
Torino, Italy
516abc
 Add to my agenda
04:20 PM
    L   
IVP meta-analysis (2): relation between the depth of excised cone and future risk of adverse pregnancy outcomes
Susanne Krüger Kjær
Epidemiologist, Division for Cancer Epidemiology, Danish Cancer Society Research Center
Copenhagen, Denmark
516abc
 Add to my agenda
05:20 PM
    L   
Conclusions
Marc Arbyn
Unit of Cancer Epidemiology, Scientific Institute of Public Health
Brussels, Belgium
516abc
 Add to my agenda
05:30 PM
Evening Symposium - Sponsored By Gen-Probe - CLINICAL PERFORMANCE OF THE APTIMA HPV ASSAY IN REFERRAL AND SCREENING POPULATIONS
 710
 Show details

   L   
New Developments in HPV mRNA Testing
Heather A. Cubie
Edinburgh, UK
710
 Add to my agenda

   L   
The Relative Clinical Performance of the APTIMA HPV Assay
Sam Ratnam
Director, Newfoundland Public Health Laboratory
St. John's, Canada
710
 Add to my agenda